Retatrutide is a weight loss (glp-1/gip/glucagon) peptide. Typical research dosing is once weekly injection, and the body of supporting research is phase 3 clinical trials.
How to source retatrutide in the Philippines
Retatrutide is still in Phase 3 trials, has no FDA approval anywhere, and is not stocked by any Philippine pharmacy. Buyers source 30mg lyophilized vials through research peptide suppliers shipping cold-chain to NAIA. Always verify a third-party COA per batch before reconstituting.
Retatrutide is a novel triple-agonist peptide developed by Eli Lilly that simultaneously activates three metabolic receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This triple-action mechanism makes it the most potent weight loss compound ever studied in clinical trials.
In a Phase 2 trial published in the New England Journal of Medicine (2023), participants on the highest dose (12mg) achieved an average body weight reduction of 28.7% over 48 weeks — more than double the effect of early GLP-1 drugs. This has made Retatrutide highly sought after in the biohacking and weight loss communities, including in the Philippines.
While not yet FDA approved (currently in Phase 3 trials), research-grade retatrutide is widely available through peptide suppliers. Users consistently report dramatic fat loss with good tolerability, particularly compared to semaglutide. Browse all weight loss peptide options to compare, or verify your supplier with the COA verification guide.
GLP-1 Agonism: Activates GLP-1 receptors in the brain and pancreas to suppress appetite, slow gastric emptying, and improve insulin secretion. This is the same mechanism as Ozempic and Mounjaro.
GIP Agonism: Activates GIP receptors which synergize with GLP-1 to enhance insulin response and are thought to reduce the nausea commonly associated with GLP-1 drugs alone.
Glucagon Agonism: This is what makes Retatrutide unique. Glucagon agonism directly increases metabolic rate (thermogenesis) and enhances fat oxidation — particularly visceral fat. This explains the superior weight loss results compared to dual-agonists.
Retatrutide is not commercially available in the Philippines — Eli Lilly's Phase 3 trials are still in progress and no branded product is FDA Philippines-registered. Every retatrutide protocol running in Manila, Makati, BGC, or Cebu in 2026 is research-grade. There is no Mercury Drug or Watsons option for this compound.
The research-grade route runs through the same supplier network that ships semaglutide and tirzepatide. Cold-chain handling is the most critical of the three GLP-class peptides — retatrutide degrades faster at room temperature, so insulated overnight delivery from a verified local supplier is the only sensible route. Lalamove same-day with a hard-sided cooler is the standard.
Self-directed retatrutide protocols in the Philippines are typically guided by a Salcedo or Legazpi wellness clinic doctor for bloodwork and dose review, even though the prescription itself does not exist. Expect to pay PHP 4,500–8,000 per consult for a doctor with peptide-specific clinical experience. Bloodwork (CBC, CMP, lipid panel, HbA1c) at Hi-Precision or Healthway runs PHP 3,500–5,500.
Makati Medical Center — endocrinology · Makati
Bloodwork and clinical review only; will not prescribe research compounds
St. Luke's Medical Center BGC — wellness medicine · BGC
Some MDs review research peptide protocols informally; no prescription possible
Hi-Precision Diagnostics · Multi-city
Standard pre/post bloodwork; covers Metro Manila, Cebu, Davao
Not applicable — no retail availability · —
Retatrutide is Phase 3 only; research-grade is the only Philippines route
| Item | PHP | USD | Source |
|---|---|---|---|
| Research-grade retatrutide 10mg vial | ₱5,500–8,500 | $98–152 | Local supplier with COA, May 2026 |
| Research-grade retatrutide 30mg vial | ₱14,500–19,500 | $260–350 | Bulk pricing, May 2026 |
| Wellness clinic consult (peptide-experienced MD) | ₱4,500–8,000 | $80–143 | Salcedo / Legazpi cluster |
| Pre/post bloodwork panel | ₱3,500–5,500 | $63–98 | Hi-Precision / Healthway |
Customs & import reality
Retatrutide research-grade is treated identically to semaglutide and tirzepatide by BOC — personal-use research quantities are tolerated, commercial quantities are not. Because no branded product exists, customs is unlikely to recognize the compound name; suppliers typically ship invoiced as "research peptide" rather than by chemical name. Cold-chain failures during BOC inspection are the most common loss mode — verify your supplier's reshipment policy before ordering.
| Phase | Dose | Frequency | Duration |
|---|---|---|---|
| Starting | 2mg | Once weekly | Weeks 1–4 |
| Titration 1 | 4mg | Once weekly | Weeks 5–8 |
| Titration 2 | 8mg | Once weekly | Weeks 9–16 |
| Maintenance | 8–12mg | Once weekly | Ongoing |
Always start at the lowest effective dose and titrate up gradually.
Nausea is common as your body adjusts. Appetite begins to decrease. Some report feeling full very quickly after eating small amounts.
Nausea typically subsides. Food noise begins to quiet. First noticeable weight loss (often 1–3kg) from caloric restriction.
Steady weight loss continues (typically 1–2kg/week when combined with modest dietary improvements). Energy often improves.
Most users report being at or near their maintenance phase. Weight loss slows as body composition improves. Visceral fat reduction becomes visible.
Sourcing partner
Most readers of this site order from Primara Labs, which ships verified research-grade Retatrutide 10mg across the Philippines with same-day Metro Manila delivery. New customers get 10% off the first order.
View Retatrutide on Primara LabsRetatrutide is not available at any Filipino pharmacy or clinic — it remains a Phase 3 investigational compound globally. Research-grade sourcing is the only path. For Philippines pricing, supplier verification, and COA red flags, see our Retatrutide Philippines 2026 guide. For the legal status of research peptides in the Philippines, see our legality guide. Then browse the community-verified supplier list.
Citations supporting the clinical claims on this page. Each entry links to the primary record.
Retatrutide Phase 2 — obesity
TrialJastreboff AM et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." N Engl J Med 2023;389:514-526.
DOI: 10.1056/NEJMoa2301972Retatrutide Phase 2 — type 2 diabetes
TrialRosenstock J et al. "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial." Lancet 2023;402(10401):529-544.
DOI: 10.1016/S0140-6736(23)01053-XRetatrutide MASLD trial
TrialSanyal AJ et al. "Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Phase 2a Trial." Nat Med 2024;30:2037-2048.
DOI: 10.1038/s41591-024-03018-2TRIUMPH-1 / TRIUMPH-3 — Phase 3 protocols
TrialEli Lilly. "A Study of Retatrutide (LY3437943) in Adult Participants With Obesity and Hypertension." ClinicalTrials.gov NCT05882045.
SourceTriple-agonist mechanism review
MechanismCoskun T et al. "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycaemic control and weight loss: From discovery to clinical proof of concept." Cell Metab 2022;34(9):1234-1247.e9.
DOI: 10.1016/j.cmet.2022.07.013Risk · Disclosure · Editorial Status
This page is editorial information for adults researching peptide therapy. It is not medical advice, not a prescription, and not an endorsement of any specific product, supplier, or protocol. Side effects can be serious and individual response varies. Talk to a licensed physician — ideally one with peptide-specific clinical experience — before starting any compound, adjusting a dose, or discontinuing therapy.
In the Philippines, GLP-1 medications are prescription-only under FDA Philippines regulation. Research-grade peptides occupy a regulatory gray area: import for personal research use is generally tolerated, but the Bureau of Customs reserves the right to inspect and detain shipments. Do not import for resale.
Editorial Status
Independent · Non-clinical
Affiliation
Not a clinic · Not a pharmacy
Last Updated
May 7, 2026
